Form 4: Arrowhead Director Receives RSU Grant

Arrowhead Pharmaceuticals Director Victoria Vakiener was granted 7,819 restricted stock units, vesting in December 2026.

Summary

• Victoria Vakiener, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 7,819 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on December 16, 2025.
• The RSUs were granted at a price of $0, indicating they are part of compensation.
• The shares will vest in a single installment on the first anniversary of the grant date, contingent on Ms. Vakiener's continued service to the company.
• Following this transaction, Ms. Vakiener beneficially owns 45,763 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning interests but not a significant market-moving event on its own. It reflects standard corporate governance practices.

Positives

• The grant of restricted stock units aligns the director's interests with those of shareholders, as vesting is contingent on continued service and potential stock price appreciation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned and transparent compensation event.

Future Outlook

NA

Industry Context

This is a routine insider compensation filing. Equity grants like RSUs are common practice in the biotechnology and pharmaceutical industry to attract and retain executive talent and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice for executive and director compensation across publicly traded companies, including those in the biotechnology sector like Arrowhead Pharmaceuticals.
• Companies such as Moderna (MRNA) and BioNTech (BNTX) frequently utilize RSU grants as a component of their non-employee director compensation packages to incentivize long-term commitment and performance.
• The vesting schedule of one installment on the first anniversary of the grant date is a common structure for director RSU grants, aiming to retain directors for at least a year post-grant.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to a director is a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging long-term value creation. It represents a dilution of existing shares upon vesting, but is a standard cost of governance.
• Management: Reinforces the compensation structure for key personnel.

Next Steps

• The 7,819 restricted stock units are expected to vest on December 16, 2026, subject to the director's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine restricted stock unit grant to a director, which is a standard compensation practice aimed at aligning management interests with long-term shareholder value. It does not present new information that would fundamentally alter the investment thesis for Arrowhead Pharmaceuticals, nor does it indicate any significant operational or financial changes. Therefore, a 'hold' recommendation is appropriate as this event alone is not a catalyst for a 'buy' or 'sell' decision.

Keywords

Arrowhead Pharmaceuticals, ARWR, Victoria Vakiener, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Compensation, 10b5-1 Plan